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Glioblastoma (GBM) tumors are fast-growing and invasive. We found that ODZ1 which 
is mainly expressed in fetal brain, plays a crucial role in the migration and proliferation 
of GBM stem-like cells (GSCs). Introduction of the entire ODZ1 or its intracellular 
fragment into ODZ1-deficient cells promotes cytoskeletal remodelling, migration and 
invasion by using 2D and 3D substrates and xenograft models. Moreover, ODZ1 increases 
the proliferation rate of GSCs in culture and generates bigger tumor masses in the brain 
of xenografted mice. Consistently, higher levels of ODZ1 are correlated with lower 
survival both in patients and xenografts. ODZ1 promotes the transcriptional activation of 
RhoA and ODZ1-induced cytoskeletal remodelling, proliferation and invasion activities 
were blocked by inhibiting RhoA-ROCK axis. Overall, we describe a novel cancer-
associated gene involved in the progression of glioblastoma, providing a putative 
prognostic marker and a new target for therapeutic strategies.  
  
Statement of significance  
ODZ1 is a transmembrane protein involved in embryonic brain development but no 
evidence exists for its role in cancer. In the present study, we demonstrate that ODZ1 
supports the proliferation and invasion capabilities of glioblastoma stem-like cells and its 









Glioblastoma is the most common brain tumor in adults and is associated with reduced 
life expectancy, ranging between 12 and 15 months (1). This aggressiveness is mostly 
due to the rapid growth and the invasive capacity of tumor cells. Even after complete 
resection of the tumor, local invasiveness eventually leads to regrowth of a recurrent 
tumor (2). Current therapeutic regimens do not adequately address the disseminated 
disease burden and rapid growth associated with infiltrative GBMs. Thus, there is an 
urgent need to develop novel treatments to specifically target the invasive and 
proliferative capacities of this tumor. Teneurins are philogenetically conserved type II 
transmembrane proteins (3). ODZ1 (Teneurin-1, TNM1), which is located on the 
Xchromosome, has an intracellular domain with two nuclear localization signals and may 
exert transcriptional regulation functions (4). ODZ1 is mainly expressed in the brain 
during the embryonic development (reference?). It has been demonstrated that GBM 
contains hierarchies with highly tumorigenic cells that display stem cell features on top 
of them (5). These GBM stem-like cells (GSCs) are governed by molecular mechanisms 
active in brain development, including Notch, Wnt, BMP, TGF  and receptor tyrosine 
kinase pathways (6). Moreover, there are many examples of genes that play essential roles 
in embryonic development and are also involved in promoting or facilitating cancer in 
adult tissues (7-9). As a representative example, the Hedgehog family of proteins plays 
an instructional role during the development of many metazoans and is implicated in stem 
cell maintenance and tissue repair, but also confers growth promoting and survival 
capabilities to cancer cells (10). So far, expression analyses by using a network of 
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differentially expressed genes or oligo-based DNA arrays, have suggested an association 
of ODZ1 with prolactin pituitary tumor metastasis (11) and papillary thyroid carcinoma 
(12). However, no direct evidence exist that ODZ1 is involved in any process aimed at 
inducing tumorogenesis or facilitating tumor progression. Recently, we showed that 
activation of Rho GTPases Rac and RhoA contributed to the invasive capacity of a 
subpopulation of GBM stem-like cells (GSCs) isolated from the peritumoral tissue (13). 
Rho GTPases are key regulators of cytoskeleton dynamics and cell polarity, cell cycle 
progression, cell migration and metastasis (14), which indicates their potential use as 
therapeutic targets in cancer. Although there is little understanding on the activity of 
RhoA in primary GSCs, reduced activation of this GTPase correlates with decreased 
invasive capacity of GSCs (15, 16). Targeting upstream regulators or Rho effectors, alone 
or in combination with other chemotherapeutic agents might provide effective therapeutic 
opportunities in different tumors, including glioblastoma.  
We have analyzed the role of ODZ1 in GSCs and found that this protein is needed for 
neurosphere-containing cells to bind to the substrate and emit protrusions that enable them 
to migrate and invade the surrounding environment. ODZ1 is also key to facilitate 
proliferation of GSCs. Xenograft animal models show that the presence of ODZ1 
increases the spreading and growth of the tumor and reduces survival. We also showed 
that ODZ1 exerts these tumor-facilitating activities by inducing the expression of RhoA 
and activation of downstream ROCK kinases.   
  
Results  
ODZ1 expression in GSCs. In normal tissues ODZ1 is mainly expressed in the 
developing brain (Supplementary Fig. S1). We analyzed the expression of ODZ1 in more 
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than sixty samples of neurosphere cultures derived from GBM patients. Although the 
mRNA levels of ODZ1 were very heterogeneous among samples, there were two  
GSC cultures, G104 and G59, with no or very low expression of this gene (Supplementary 
Fig. S2A and B).  Interestingly, these GSCs did not show the typical morphological 
changes when they were induced to differentiate (adhesion to the substrate, cytoplasmic 
extensions) but remained forming neurospheres (Supplementary Fig. S2C). However, the 
gene expression pattern of differentiation was indistinguishable from that of ODZ1-
expressing GSCs as determined by upregulation of the astrocytic marker GFAP and 
downregulation of the stem cell marker CD133 (Supplementary Fig. S2D). Then, we 
studied the cause for the lack of ODZ1 expression. Microarray-based comparative 
genomic hybridization revealed that G104 carried a 6 Mb genomic deletion that included 
the entire ODZ1 gene (Supplementary Fig. S3A). This deletion was present in both GSCs 
and GBM tissue obtained during surgery (Supplementary Fig. S3B). Data from the 
cBioPortal for cancer genomics (17, 18) revealed a frequency of ODZ1 gene deletion 
lower than 1% in glioblastoma samples. However, it has also been detected in other 
cancers with higher frequencies including adrenocortical carcinoma (9%) and brain low 
grade gliomas (3.4%) (Supplementary Fig. S3C). Since ODZ1 gene is not deleted in G59 
GSCs, we studied a potential repression by promoter methylation. Although we did not 
find a canonical CpG island spanning the ODZ1 promoter, treatment of G59 with the 
demethylating agent 5-aza-2'-deoxycytidine increased more than 3-fold the expression of 
ODZ1 (Supplementary Fig. S3D). Thus, we cannot rule out that methylation contributes 
to the very low levels of ODZ1 in these cells. Unless otherwise indicated, G59 and G104 
cells, named here as ODZ1-deficient GSCs, were used as cell models and all results were 
confirmed in both models.  
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ODZ1 expression promoted spreading of GSCs in a chicken embryo model and 
reduced survival in GBM patients. In order to study the function of ODZ1 in the GBM 
stem-like cell compartment, we transfected ODZ1-deficient GSCs with ODZ1  
(Fig. 1A). Ingenuity Pathway Analysis (IPA) of microarray gene expression data of these 
cells showed that cell morphology and cellular assembly and organization are among the 
top network functions associated with the expression of ODZ1 (Supplementary Table S1). 
Interestingly, ODZ1-transfected cells recovered the phenotypic features of cells 
undergoing differentiation, showing adhesion to the substrate and protrusion formation 
with F-actin location at the edges of projections (Fig. 1B and C). There was also an 
increase in the number of rounded cells with short protrusions and elongated cells with 
long protrusions, and a reduction in the number of rounded cells with no protrusions (Fig. 
1D). Similar pattern was observed in cells cultured on a laminin-coated surface, although 
there was a significant increase in the number of cell projections (star-shaped cells) (Fig. 
1E). We also observed that cells were able to migrate out of the neurosphere when they 
were forced to express ODZ1 and this migration promoting effect was detected in 
neurospheres cultured into different matrices made of (collagen I either alone or in 
combination with hyaluronic acid or matrigel) (Fig. 1F). To further analyze the capacity 
of ODZ1 to induce migration, we transfected ODZ1-expressing GSCs with shRNAs 
targeting this gene. One of them, shRNA-2, significantly downregulated the endogenous 
levels of ODZ1 protein (Fig. 2A) and promoted a 6-fold increase in the number of rounded 
cells in suspension that formed neurospheres over time (Fig. 2B and C). Moreover, GSCs 
with downregulated levels of ODZ1 tended to be less dispersed and more aggregated 
when injected into chicken embryos as compared with the same cells transfected with an 
irrelevant shRNA (Fig. 2D). Conversely, ODZ1-deficient cells transfected with ODZ1 
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acquired the ability to propagate through the surrounding tissue in the embryo (Fig. 2E). 
Interestingly, patients having GBM tumors with high expression of ODZ1 had a lower 
mean survival than those with reduced ODZ1 levels as determined by analysing data of 
the Repository for Molecular Brain Neoplasia Database (Rembrandt) (Fig. 2F).   
ODZ1 promoted more aggressive tumors in xenografted mice. In order to translate 
our previous results to a more physiologically relevant in vivo model, we studied the role 
of ODZ1 in the tumor development and survival of xenografted mice. First, different 
GBM cell lines were analyzed for their levels of ODZ1. Among those with the lowest 
expression (Fig. 3A), we chose RG1 because it efficiently and rapidly generates tumors 
in immunodeficient mice (19). ODZ1-transfected RG1 cells promoted larger tumors than 
their control counterparts as determined on T2-weighted MRI scans (Fig 3B), and 
consequently the survival of these animals was significantly reduced (Fig. 3C), which is 
consistent with the survival data in GBM patients. In a second model, ODZ1deficient 
GSCs were transfected with either the entire ODZ1 or its cytoplasmic fragment (Fig. 3D 
and E), the 45 kDa N-terminal part of the protein. We showed that this fragment (icODZ1) 
was sufficient to recover the expected morphology of GSCs undergoing differentiation 
(Fig. 3F). These transfectants were xenografted into the brain of immunodeficient mice 
and about 5 months later animals were sacrificed. Immunohistochemical analysis of brain 
slices confirmed bigger tumors in mice grafted with ODZ1- and icODZ1-containing cells 
as determined by using different markers including vimentin that specifically stained 
human tissue and served to delimitate the extension of the tumor, human GFAP that is 
expressed in tumor cells, and Ki67 as a proliferation marker (Fig. 3G).   
The intracellular fragment of ODZ1 is a key mediator in promoting morphologic 
changes in differentiating GSCs. ODZ1-deficient GSCs were transfected with the entire 
 
  9  
ODZ1, the intracellular fragment or the extracellular plus the transmembrane regions 
(ecODZ1) (Fig. 4A). These cells were cultured under differentiation conditions and four 
days later filamentous actin (F-actin) was stained with phalloidin. As shown in  
Fig. 4B, both ODZ1 and icODZ1 promoted long actin-filled protrusions but cells 
transfected with ecODZ1 behaved as the control cells and showed little changes in 
morphology.  icODZ1 also promotes localization of CAP/Ponsin to focal adhesions (Fig. 
4C), a protein that has been shown to reorganize F-actin at cell-extracellular matrix 
contacts (20). An epithelial-to-mesenchymal-transition-like program highlighted by a T-
cadherin to N-cadherin switch has been described in GBM cells associated with invasion 
and a worse prognosis (21). Interestingly, N-cadherin along with other mesenchymal 
markers such as Vimentin and Snail were upregulated whereas Tcadherin was 
downregulated in icODZ1-transfected GSCs (Fig. 4D and E). Moreover, consistent with 
the chemoresistance associated with the mesenchymal phenotype, cells expressing 
icODZ1 were more resistant to temozolomide, a nitrosourea commonly used in GBM 
patients (Fig. 4F). We further evidenced that icODZ1 was not only able to promote 
morphological changes but also to induce or facilitate migration in both 2D and 3D 
substrates. Wound healing assays showed that ODZ1 and icODZ1 but not ecODZ1 
efficiently repopulated the scratch area (Fig. 5A and B). Moreover, invasion assays in 3D 
collagen matrices, which is more representative of the tumor niche than 2D surfaces, 
demonstrated that although ODZ1 promoted migration of GSCs through the gel (about 3-
fold increase relative to control), icODZ1 was significantly more efficient (more than  
6-fold increase relative to control) (Fig. 5C and D). Thus, these results suggest that GSCs 
with higher levels of ODZ1 would have an advantage to migrate and invade the 
surrounding environment.   
 
  10  
The intracellular fragment of ODZ1 mediates its activity on GSCs by transcriptional 
activation of RhoA. Rho GTPases regulate the morphologic chances associated with 
motility and invasion by controlling the actin polymerization and actomyosin contraction 
(22). Thus, we asked whether ODZ1 could mediate its activity through a Rho protein. 
First, ODZ1-deficient GSCs were transfected with an inducible icODZ1-containing 
vector. Induced expression of icODZ1 was followed by a specific increase in the mRNA 
levels of RhoA but not Rac1 or Cdc42 (Fig. 6A). icODZ1 is directly targeted to the 
nucleus (Fig. 6B), where it may exert transcriptional regulation activities. This could 
explain the stronger effects of icODZ1 when compared with the membrane-associated 
protein. We showed that icODZ1 was able to activate the RhoA promoter. In a RhoA 
promoter-luciferase reporter assay, icODZ1 induced a 5-fold increase in luciferase 
activity (Fig. 6C). Total RhoA protein expression and RhoA activity, as determined by 
the levels of GTP-bound RhoA, were also upregulated by icODZ1 (Fig. 6D). Activation 
of RhoA was further determined by analyzing phosphorylation of MLC2, a downstream 
mediator of RhoA-ROCK signaling. As shown in Fig. 6E, icODZ1 and to a lesser extent 
ODZ1 but not ecODZ1 increased the level of pMLC2 as detected by 
immunofluorescence. These results indicate that icODZ1 promotes expression of RhoA 
and activation of the RhoA-ROCK axis. To confirm this, we analyzed the localization of 
Ponsin at focal adhesions, a hallmark of ODZ1 activity, in the presence of a RhoA 
inhibitor, a ROCK inhibitor or by using siRNAs against ROCK1 and ROCK2 (Fig. 7A-
D). In all cases, Ponsin accumulation to projection tips was efficiently blocked by the 
inhibition strategies. Moreover, icODZ1-promoted invasion of GSCs in a 3D collagen 
matrix, another hallmark of ODZ1 activity, was blocked with ROCK inhibitor. The 
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presence of H1152 gave rise to a 4-fold decrease in the invasion capacity of icODZ1-
expressing cells (Supplementary Fig. S4A and B).   
ODZ1 increases the proliferation rate of GSCs. A consistent observation in cultures of 
ODZ1-deficient GSCs transfected with ODZ1 or icODZ1 is that they grow faster than 
control or ecODZ1-transfected cells. This effect was quantitated over a period of 48 h and 
found that the proliferation rate in icODZ1 was about twice higher than control or 
ecODZ1-transfected cells. ODZ1 also promoted a clear increase in proliferation although 
at a slightly lower level than icODZ1 (Fig. 7E). Consistent with our previous data, ROCK 
inhibitor reduced the proliferation promoted by icODZ1 and ODZ1 but had no effect on 
cells expressing ecODZ1 (Fig. 7E). This result was confirmed by using a Rho inhibitor 
which significantly reduced ODZ1-mediated proliferation, although in this case the effect 
was detected at 72 h (Supplementary Fig. S5A). RhoA activation is crucial for the cell 
cycle G1-S progression through the regulation of CDKN/Cip family of CDK inhibitors. 
Microarray analysis of gene expression showed that among members of this family 
CDKN1A (p21) and CDKN2C (p18) were downregulated in ODZ1-transfected cells 
(Supplementary Fig. S5B) which are both known to be regulated by RhoA (23).   
  
Discussion  
Although in recent years a great effort has been made to understand the molecular features 
of GBM through tumor genetics and mouse modelling, few of these findings have entered 
into clinical practice to date. Thus, there is still a need to deepen into the mechanisms 
used by GBM cells to become invasive and resistant to chemotherapy.  
We have focussed this work on ODZ1 gene, which is predominantly expressed in the 
developing brain. There are no previous evidences to support the role of ODZ1 in cancer. 
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However, Ingenuity Pathway Analysis (IPA) of gene expression microarray data 
generated by our group revealed that 149 cancer-associated genes are differentially 
expressed in GSCs transfected with ODZ1. Two GSC samples with no or very little 
expression of ODZ1 were used as ODZ1-deficient GSCs in this work. GSCs grow in 
suspension forming neurospheres and they attach to the substrate and acquire a flat and 
extended morphology under differentiation conditions (24). We found that 
ODZ1deficient GSCs do not acquire the morphology of differentiating cells, although the 
genetic program of differentiation appears to be normal. The capacity of ODZ1 to control 
adherence to extracellular matrix and morphological changes of GSCs is in line with the 
IPA network analysis which showed that cell morphology, cellular assembly and cell-cell 
interactions are among the top cellular functions of ODZ1. Morphological changes are 
driven by cytoskeletal reorganization, which is a key feature of cell migration. We showed 
that ODZ1 promotes actin cytoskeletal remodelling, migration and invasion of GSCs as 
determined by using 2D and 3D in vitro systems and a xenograft model of chicken 
embryo, where ODZ1-expressing GSCs efficiently invade the surrounding environment. 
Previous work in Drosophila suggested that the ODZ1 homolog Ten-m is involved in 
remodelling of the postsynaptic cytoskeleton, physically linking the synaptic membrane 
to the cytoskeleton (25). Moreover, it has been described that chicken ODZ1 interacts 
with CAP/ponsin, which in turn binds to vinculin that could anchor the intracellular region 
of ODZ1 to the actin cytoskeleton (4). Consistently, we found that ODZ1 promoted long 
actin-filled protrusions and the localization of ponsin at projection tips in GSCs, which 
streghthen the role of ODZ1 as a regulator of cytoskeletal remodelling and provides the 
first evidence of this ODZ1 activity in cancer cells. Actin cytoskeleton has key roles in 
cell cycle progression (26). Thus, not surprisingly, ODZ1 increases the proliferative 
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capacity of GSCs. Invasiveness and proliferation are two hallmarks of GBM and 
strategies aimed at targeting pathways that control these processes, mainly in GSCs, are 
the focus of intensive research (2729). Rho GTPases are key players in controlling 
cytoskeleton dynamics, cell migration and cell division (14). Elevated levels of RhoA 
have been described in clinical samples of high-grade gliomas (30). Interestingly, ODZ1 
is able to induce the expression and activation of RhoA in GSCs. Moreover, RhoA is 
transcriptionally activated by the intracellular fragment of ODZ1 (icODZ1) that is 
translocated to the nucleus. icODZ1, which lacks a DNA binding domain, is likely to 
interact with transcriptional regulators to control gene expression. In line with this, it has 
been described that icODZ1 binds to the transcriptional repressor MBD1 (4). Further 
studies will be needed to decipher how icODZ1 activates gene expression. By using 
different inhibition strategies, we demonstrated that RhoA signaling mediates the 
cytoskeletal remodelling and the increase in cell migration, invasion and proliferation 
promoted by ODZ1. Although RhoA has been tipically associated with rounded 
morphology and amoeboid motility, there is insufficient functional evidence for the role 
of RhoA in promoting this type of cell migration in GBM cells (31). In line with our data, 
high levels of RhoA activity have been associated with elongated morphology and 
mesenchymal-type invasion in different cancer cell lines (32, 33). Shifts towards a 
mesenchymal phenotype appear to be a common pattern of disease progression in GBM 
patients and are reminiscent of epithelial-mesenchymal transitions (EMT) of epithelial 
tumors (34). We demonstrate that ODZ1-induced changes in GSCs are associated with 
the acquisition of a mesenchymal phenotype characterized by an EMT-like gene 
expression signature. Mesenchymal GBM show aggressive dissemination, often with 
multifocal presentation as well as resistance against chemotherapy. Consistently, ODZ1-
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expressing GSCs are more invasive and more resistant to temozolomide. The relevance 
of Rho-ROCK pathway in promoting migration and growth of GBM cells has been 
described by using established cell lines (35, 36). Our data provides a novel ODZ1-RhoA-
ROCK axis for therapeutic strategies against a pathway controlling key activities in 
GSCs. Blockade of RhoA expression or activation through its upstream regulator ODZ1 
has the advantage that this protein is located at the cell membrane which facilitates 
inhibition strategies with small molecules or antibodies. Additionally, contrary to other 
integral membrane proteins associated with GBM such as EGFR that is widely expressed 
in a number of adult tissues, or RhoA which is ubiquitously expressed across tissues and 
is involved in a number of cellular functions, ODZ1 expression is mostly restricted to 
fetal brain, which could make ODZ1-targeted therapies more tumor-specific limiting their 
side  
effects.  
In summary, our study shows for the first time that ODZ1, a protein that participates in 
the embryonic development of the brain, is also involved in cancer progression by 
promoting the growth and invasion capabilities of glioblastoma stem-like cells. Thus, 
these data provide a novel and promising target to develop therapeutic strategies aimed at 
blocking the two features that make glioblastoma so aggressive and lethal.  
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Materials and Methods  
Primary cell cultures. Cell cultures from tissue specimens used in this study have been 
previously characterized and described by our group (13, 37). GSCs were maintained in 
serum-free DMEM/F12 medium (Life Technologies, Paisley, UK) as described and 
plated at a density of 3x106 live cells/60-mm plate. Primary neurospheres were 
dissociated every 4 days to facilitate cell growth. To promote differentiation, 
neurospheres were cultured in the same medium but in the presence of 10% FBS for four 
days. Established GBM cell line RG1 (L0627), kindly provided by Dra. Rosella Galli, 
was cultured as previously described (19). Cell proliferation and cell survival were 
evaluated with Alamar Blue bioassay (Life Technologies) using a Synergy HT reader 
(BioTek, Winooski, VT).  
When indicated, cells were treated with 5 M ROCK inhibitor H1152 (Tocris  
Bioscience, Bristol, UK), 1 g/ml Rho Inhibitor I (Cytoskeleton, Inc., Denver, CO) or 
100 M Temozolomide (Merck, Whitehouse Station, NJ).   
In vivo models. Tumor xenografts in chicken were established as previously described  
(13). Briefly, GSCs were labeled with CFDA SE Cell Tracer (Invitrogene, Carlsbad, CA) 
and microinjected into the embryos limb bud. After 24 hrs of incubation, embryos were 
fixed in 4% PFA, and the dissected limbs monitored by confocal microscopy.  
Images shown are the integration of all Z-stacks taken along the dorsal-ventral plane at 
15 m intervals to cover the whole limb.   
For tumor xenografts in mice we followed a procedure described elsewhere (38). This 
model was reviewed and approved by the Research Ethics and Animal Welfare  
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Committee at the Instituto de Salud Carlos III, Madrid, in agreement with the European 
Union and national directives. Briefly, 5 x 104 GBM cells were resuspended in 2 l of 
culture medium and stereotactically injected in athymic nude Foxn1nu mice (Harlan 
Laboratories, Indianapolis, IN). The injections were made into the striatum and the 
animals were sacrificed at onset of symptoms.  
Mouse magnetic resonance imaging (MRI). MRI analysis was performed in mice 
injected IP with Gd-DOTA (Dotarem, Bloomington, IN). T1W images were acquired in 
a 4.7 TBiospec BMT 47/40 spectrometer (Bruker, Billerica, MA) with a spin-echo 
sequence (Centro de Apoyo a la Investigación, CAI, Universidad Complutense, Madrid, 
Spain).  
Generation of anti-ODZ1 antibodies. Two anti-ODZ1 antibodies were generated in 
rabbits. The anti-N-terminus antiserum was raised against a GST fusion protein 
containing 40 amino acids of the N terminal region of ODZ1, and the anti-C-terminus 
included 68 aminoacids of the C terminal region. Both antibodies were purified from the 
antisera by affinity chromatography using GST-ODZ1 fusion protein-Sepharose columns, 
after preclearing of anti-GST antibodies.  
Immunofluorescence analysis. GSCs were grown on glass cover slips previously coated 
with 10 g/ml fibronectin (Sigma- Aldrich, St Louis, MO), 0.1% gelatin (Sigma) or 10 
g/ml laminin (Sigma). After 2-4 days, cells were fixed in 4% PFA for 15 min, washed 
in PBS and blocked with 0.3% Triton X-100, 1% BSA for 1 hr. Cells were incubated with 
anti-phospho-myosin light chain 2 (Ser19) (Cell Signaling, Danvers,  
MA), or anti-Ponsin (Santa Cruz Biotechnology, Santa Cruz, CA) primary antibodies. 
Then, the cells were washed with PBS and incubated with Texas red-conjugated or  
FITC-conjugated goat anti-rabbit secondary antibodies (Jackson ImmunoResearch,  
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Cambridgeshire, UK) for fluorescence detection. Actin cytoskeleton was stained with 
TRITC- or FITC-conjugated Phallodin (Sigma) and nuclei visualized with DAPI (Life  
Technologies). Samples were mounted with ProLong Gold Antifade Reagent (Life  
Technologies). Confocal images were taken with a Ti-Eclipse microscope (Nikon, Tokyo, 
Japan).  
Immunohistochemical staining. Mouse brains containing tumors generated by injection 
of ODZ1-transfected GSCs were fixed in 4% PFA. Vibratome sections (200 m thick) 
were paraffin-embedded and then consecutive semithin sections were processed and 
incubated with primary antibodies against Vimentin, GFAP and Ki67 (DAKO, Glostrup, 
Denmark) followed by horseradish peroxidase (HRP)-conjugated secondary antibodies 
and visualized by a chromogen or stained with hematoxilin-eosin.    Quantitative RT-
PCR and RT-PCR. To assess the expression of individual genes, a cDNA was generated 
and amplified using primers for human CD133, Tuj1, glial fibrillary acidic protein 
(GFAP), -Actin (Nogueira et al., 2011), T-Cadherin  
(5’TTCTGTGCGTTCTCCTGTCC3’ and 5’TCTCAGAGCAACTAAGCCGC3’) , 
NCadherin  (5’GACAATGCCCCTCAAGTGTT3’  and  
5’CCATTAAGCCGAGTGATGGT3’), Vimentin (5’TCGGCGGGACAGCAGG3’ and  
5’GGTGGACGTAGTCACGTAGC3’), Snail (5’TAGCGAGTGGTTCTTCTGCG3’ and  
5’AGGGCTGCTGGAAGGTAAAC3’),  icODZ1  
(5’ACTCAAGAGATGGAATTCTGTG3’  and  5’CTTAGTGCATGGTCAGGTG3’),  
ecODZ1 (5’ACAATGATGGACGGTGCCTT3’ and 5’GTGTCCCTCCCCTCTATGGT3’)  
ODZ1  exon1  (5’GGACCAATTGTGAATCTGCC3’  and  
5’CCTACAACCTCAGCTGGGC3’), ODZ1 exon20 (5’GGGAAGGTTTTGCAGGC3’  
and  5’CCACTGTGCTAGAGGCTGG3’),  ODZ1  exon32  
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(5’CTTGCAAGCCTGTCCTTTCC3’ and 5’CCCAGTGTTACCGATGAGC3’), and Stag2 
(5’CACGCCTGGCTAATTTTTGT3’ and 5’CAATACAGGGCAGGTGTGCT3’).  
Quantitative real-time PCR was performed in a 7000 sequence detection System (Life 
Technologies). At least three independent experiments for each quantitative PCR were 
performed.  
Expression Microarray. Total RNA from empty vector- and ODZ1-transfected cells was 
extracted using the RNeasy mini kit (Qiagen, Valencia, CA) and microarray gene 
expression analysis was performed with the Human Genome U133 Plus 2.0 array 
(Affymetrix, Santa Clara, CA). Both background correction and normalization were done 
using Robust Multichip Average algorithm. The selection of those genes differentially 
expressed was performed using a criteria based on the fold-change value. Probe sets were 
selected as significant using a logFC cut-off of 1.5. The raw data have been deposited in 
a MIAME compliant database (GEO accession number, GSE65526).  
Copy number variation analysis. DNA copy number changes were evaluated using  
Affymetrix GeneChip 250-NspI/StyI SNP microarrays as previously described (13).  
Bioinformatic analysis was performed using Affymetrix Genotyping Console 3.0.2 and 
Partek 6.5 software (Partek Incorporated, St Louis, MO).  
2D Wound Healing Assay. For the wound-healing assay, cells were seeded into collagen 
I coated 24-well plates and grown to confluence. The cell monolayers were carefully 
scratched with a 200 l pipette tip and cells were incubated in fresh medium supplemented 
with serum. To monitor the migration of cells into the wounded area, cell cultures were 
photographed under the phase contrast microscope at 0 and 24 h post wounding. Cell 
migration was expressed by the percentage of wound closure, n= 4.   3D Invasion Assays. 
Cells (105 cells/ml) were included in serum-free matrix composed of 1.7 mg/ml collagen 
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I alone (Nutacon BV, Leimuiden, The Netherlands), or collagen I combined with 2.3 
mg/ml Matrigel (BD Biosciences, Franklin Lakes, NJ) or hyaluronic acid (Sigma) into 
96-well ViewPlates (PerkinElmer, Waltham, MA) and processed as previously described 
(Sanz-Moreno et al., 2008; Ruiz-Ontañón eta l., 2013). Confocal Z slices were collected 
at 50 m, 30 m and 3 m (bottom of the well) with a Ti-Eclipse microscope.     
Transfections, Gene Silencing and Gene Reporter Assays. ODZ1-deficient GSCs were 
transfected with the entire ODZ1 cDNA, the extracellular (plus transmembrane) fragment 
(both from Origene, Rockville, MD) or the intracellular fragment, that was PCR-
amplified from ODZ1 cDNA and subsequently cloned into pCMV6. Stable transfectants 
were selected with 500 g/ml geneticin (Life Technologies). icODZ1 was subcloned in 
a tetracycline-regulated retroviral vector (39). Cells were transiently transfected with this 
vector and the expression of ODZ1 was induced in the presence of 2 g/ml doxycycline 
(Sigma).   
For ODZ1 downregulation, GSCs were transfected with ODZ1-specific shRNAs  
(Thermo Fisher Scientific, Waltham, MA) by using nucleofection. GSCs were transfected 
with ROCK1 and ROCK2 siRNAs (Dharmacon's SmartPools, Thermo Fisher Scientific) 
by Lipofectamine RNAiMAX (Life Technologies).   
Cells were co-transfected with 1 g of human RhoA promoter cloned into pGL3 vector 
(40) and 50 ng of pRSV- -gal by nucleofection. 48h post-transfection, cell extracts were 
prepared and analyzed for the relative luciferase activity by a dual-light reporter gene 
assay system (Applied Biosystems, Foster City, CA). Results were normalized for 
tranfection afficiency with values obtained with pRSV- -gal.  
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Western Blot. Total protein extracts were separated on 8 or 12% polyacrilamide gels or 
4-20% gradient gels (BioRad, Hercules, CA) and transferred to nitrocellulose. Blots were 
blocked with 5% bovine serum albumin (BSA) and incubated with antibodies against 
GAPDH,  -Tubulin (Santa Cruz Biotechnology, Santa Cruz, CA), RhoA (Cell Signaling 
Technology, Danvers, MA), ODZ1 (R&D Systems, Minneapoli, MN) and NCadherin 
(Sigma) followed by incubation with goat anti-rabbit or anti-mouse or antisheep 
conjugated to alkaline phosphatase (Sigma). Bound antibody was detected by a 
chemiluminiscence system (Applied Biosystems).  
Statistical analysis. All statistics were calculated with the SPSS statistical package 
(version 13.0). Data are presented as mean ± S.D. of at least three independent 
experiments. Differences between groups were tested for statistical significance using the 
unpaired 2-tailed Student’s t test. The significance level was set at p<0.05.    
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Figure legends  
Figure 1. Transfection of ODZ1-deficient GSCs with ODZ1 restores the morphology of 
differentiating GSCs. (A) ODZ1 protein levels in ODZ1-transfected GSCs. The levels of 
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-tubulin were analysed to assure equal loading. Transfected cells were cultured in 
differentiation medium and 4 days later their morphology (B) and the distribution of 
Factin (C) were assessed by using phase contrast or fluorescence microscopy respectively. 
(D) GSC transfectants cultured in differentiation medium were counted as a function of 
their morphology as rounded, R, rounded with protrusions, R+P, and elongated, E. 
Histograms represent the mean + S.D. (n=3; *p<0.01, **p<0.05). (E) Factin staining of 
cells differentiated onto a laminin-coated surface. (F) Phase contrast images of ODZ1-
transfected neurospheres cultured in collagen-based matrices.   
Figure 2. ODZ1 expression is sufficient to induce cell spreading in vitro and in vivo. (A) 
GSCs were transfected with different shRNAs targeting ODZ1 and the expression levels 
of this protein were determined 72 h later. The levels of -tubulin were analysed to assure 
equal loading. (B) GSCs were transfected with the most effective ODZ1specific shRNA 
(sh-2) and the number of living cells floating in the culture medium were quantitated. sh-
C, irrelevant shRNA. Values represent the mean+S.D. (n=3; *p<0.001). (C) GSCs 
transfected with ODZ1-specific shRNA-2 and EGFP formed neurospheres under 
differentiation conditions as determined by fluorescence microscopy. (D) CFDA SE-
labeled GSCs with downregulated levels of ODZ1 were injected into the chicken embryo 
limb and 24 h later cell spreading was determined by confocal microscopy. (E) ODZ1-
deficient GSCs were transfected with ODZ1 or empty vector and xenografted in chicken 
embryo as above. (F) Rembrandt data set showing the survival of GBM patients with 
differential expression of ODZ1.  
Figure 3. ODZ1-expressing tumors are more aggressive. (A) ODZ1 mRNA levels in 
different GBM cell lines by RT-PCR. Actin expression was used for signal 
normalization. (B) Representative T2-weighted nuclear magnetic resonance (NMR) 
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images showing tumors in the brain of mice xenografted with ODZ1-transfected RG1 
GBM cells. (C) Kaplan-Meier survival curves of mice harboring RG1-derived tumors 
with high or low levels of ODZ1. (D) Schematic representation of the ODZ1 protein 
showing the intracellular (IC) transmembrane (TM) and extracellular (EC) parts of the 
protein. NLS, nuclear localization signal. (E) Expression of ODZ1 and icODZ1 in 
transfected GSCs. The levels of -tubulin were analyzed to assure equal loading. (F) 
ODZ1-deficient cells were transfected with icODZ1 and cultured under differentiation 
conditions. Cell morphology was assessed after 4 days of culture. Scale bar: 50 m. (G) 
ODZ1-deficient GSCs transfected with the entire ODZ1 or its intracytoplasmic fragment 
(icODZ1) were xenografted in mice and brain sections were obtained for 
immunohistochemical analysis Note the intracranial tumor staining (brown) by using 
markers that reveal the presence of tumor cells. HE: hematoxylin-eosin staining.  Figure 
4. ODZ1 promotes actin cytoskeleton remodeling and induces a chemotherapy resistant 
mesenchymal-like phenotype. (A) RT-PCR showing the expression of ODZ1 in ODZ1-
deficient GSCs transfected the intracellular fragment (icODZ1), the extracellular plus 
transmembrane fragment (ecODZ1) or the entire ODZ1 with oligonucleotides specific for 
the ic or ec regions of the cDNA. Actin expression was used for signal normalization. 
(B) Representative confocal images of the different GSC transfectants showing F-actin 
staining. Scale bar, 10 m. (C) ODZ1-deficient GSCs expressing icODZ1 accumulates 
the focal adhesion protein ponsin at projection tips as determined by 
immunofluroescence. Scale bar: 10 m. (D) icODZ1-dependent mRNA expression levels 
of the epithelial-like marker T-Cadherin (T-Cad) and the  mesenchymal specific markers 
N-Cadherin (N-Cad), Vimentin (Vim) and Snail as determined by qRT-PCR. Histograms 
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represent the mean+S.D. (n=3; *p<0.01, **p<0.001). (E) N-Cadherin protein expression 
in transfectant GSCs. The levels of tubulin were analyzed to assure equal loading. (F) 
icODZ1-transfected GSCs were treated with 100 M TMZ and 48 h later cell viability 
was determined by using alamarBlue bioassay. Values represent the mean+S.D. (n=3; 
*p<0.001).   
Figure 5. ODZ1 promotes cell migration and invasion. (A) Micrographs of a 
woundhealing assay showing the migration of different transfectant GSCs towards the 
scratched area. (B) Quantification of migration in the wound healing assay as percentage 
of wound closure. Histograms represent the mean+S.D. (n=3; *p=0.01 compared with 
pCMV6 control). (C) Representative images of a cell invasion assay in a 3D collagen 
matrix. Nuclei were stained with DAPI. (D) Quantification of the invasion assay as 
percentage of cells detected at 30 m from the bottom. Histograms represent the 
mean+S.D. (n=3; *p<0.05, **p<0.001 compared with pCMV6 control).  
Figure 6. ODZ1 triggers the transcriptional activation of RhoA. (A) The mRNA 
expression levels of Rho GTPases RhoA, Rac1 and Cdc42 were analyzed by qRT-PCR 
in ODZ1-deficient GSCs transfected with an icODZ1-containing doxycycline-inducible 
construct. Histograms represent the mean+S.D. (n=3; *p<0.01). (B) The intracellular 
fragment of ODZ1 protein was localized within the nucleus after transfection with 
icODZ1, as determined by immunofluorescence with antibodies against the N-terminal 
part of the protein. (C) ODZ1-deficient GSCs were cotransfected with a RhoA promoter-
luciferase reporter construct and icODZ1 and luciferase activity was determined 48 h 
later. Histograms represent the mean+S.D. (n=3; *p<0.01). (D) GTPbound RhoA and 
total RhoA protein expression in GSC transfectants were determined in ODZ1-deficient 
cells transfected with icODZ1. The levels of -tubulin were analyzed to assure equal 
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loading. (E) ODZ1 transfectants were analyzed for the expression of phosphorylated 
MLC2 by immunofluorescence. Single plane confocal micrographs were taken under the 
same intensity settings. Scale bar: 10 m.   
Figure 7. ODZ1 increases focal adhesions and promotes proliferation through RhoA 
activation. (A-D) The expression of the focal adhesion protein Ponsin is shown in 
icODZ1-transfected GSCs in the presence or in the absence of different inhibitors of the  
RhoA-ROCK pathway, Rho inhibitor I, ROCK inhibitor H1152 and siRNAs against 
ROCK1 and ROCK2. Single plane confocal micrographs were taken under the same 
intensity conditions. Scale bar: 5 m. (E) GSC transfectants were cultured in the presence 
or in the absence of ROCK inhibitor H1152 for the indicated time intervals and 
proliferation was assessed by Alamar Blue assay. Histograms represent the mean+S.D. 
(n=3; *p=0.001, **p<0.001 compared with untreated control).  
Supplementary Figure S1. ODZ1 is mainly expressed in fetal brain. Microarray data for 
ODZ1 expression in different tissues were taken from the BioGPS data set  
(http://biogps.org).  
Supplementary Figure S2. Morphological changes in GSCs undergoing differentiation 
depend on ODZ1. (A) mRNA levels of ODZ1 in different GSC samples were determined 
by quantitative RT-PCT. (B) ODZ1 protein expression in GSC samples. Tubulin was 
used to assure equal loading.  (C) Neurospheres were disgregated and cultured in the 
presence of FBS. Morphological changes of differentiating cells were visualized after 4 
days of culture. (D) Gene expression levels of markers associated with differentiation of 
GSCs were determined by quantitative RT-PCR. S, GSCs. D, GSCs undergoing 
differentiation. Histograms represent the mean+S.D. (n=3; *p<0.01,  
**p<0.05).  
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Supplementary Figure S3. Genetic basis for the lack of ODZ1 expression. (A) 
Representation of the X-Chromosome showing the size of the deleted genomic fragment 
and the deleted genes in G104 GSCs. (B) Amplification of different exons of the ODZ1 
gene from GSC-derived genomic DNA. Stag2 was used as a positive control of 
amplification. (C) ODZ1 gene deletion frequency in different tumors was obtained from 
the cBioPortal for cancer genomics. (D) G59 GSCs were treated with the DNA 
demethylating agent 5-aza-2'-deoxycytidine (3 M 5-Aza) for 3 days and the ODZ1 
expression was determined by quantitative RT-PCR. Histograms represent the 
mean+S.D. (n=3; *p<0.01).  
Supplementary  Figure  S4.  Inhibition  of  ROCK  blocks  icODZ1-promoted  
invasiveness. (A) Invasion assay of GSC transfectants in a 3D collagen matrix with or 
without H1152. DAPI-stained cells were visualized by confocal microscopy at different 
focal planes. (B) Quantification of the invasion assay as percentage of cells detected at  
20 m from the bottom.  ecODZ1-expressing cells were included here for comparison.  
Histograms represent the mean+S.D. (n=3; *p=0.0005).   
Supplementary Figure S5. Rho inhibition reduces cell proliferation induced by ODZ1. 
(A) GSC transfectants were cultured in the presence or in the absence of Rho inhibitor I 
for the indicated time intervals and proliferation was assessed by Alamar Blue assay. 
Histograms represent the mean values+SD. (n=3; *p=0.005 compared with untreated 
control). (B) Gene expression microarray data showing the fold change of CDKN/Cip 
family of CDK inhibitors in ODZ1-transfected cells compared with control cells. Dashed 
line marks the fold change cut-off (log2FC>0.5) used in the microarray  
analysis.   
Supplementary Table S1. Ingenuity cellular functions and disorders associated with  
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ODZ1.  
